| First Author | Makanji Y | Year | 2014 |
| Journal | Endocr Rev | Volume | 35 |
| Issue | 5 | Pages | 747-94 |
| PubMed ID | 25051334 | Mgi Jnum | J:306042 |
| Mgi Id | MGI:6708293 | Doi | 10.1210/er.2014-1003 |
| Citation | Makanji Y, et al. (2014) Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev 35(5):747-94 |
| abstractText | When it was initially discovered in 1923, inhibin was characterized as a hypophysiotropic hormone that acts on pituitary cells to regulate pituitary hormone secretion. Ninety years later, what we know about inhibin stretches far beyond its well-established capacity to inhibit activin signaling and suppress pituitary FSH production. Inhibin is one of the major reproductive hormones involved in the regulation of folliculogenesis and steroidogenesis. Although the physiological role of inhibin as an activin antagonist in other organ systems is not as well defined as it is in the pituitary-gonadal axis, inhibin also modulates biological processes in other organs through paracrine, autocrine, and/or endocrine mechanisms. Inhibin and components of its signaling pathway are expressed in many organs. Diagnostically, inhibin is used for prenatal screening of Down syndrome as part of the quadruple test and as a biochemical marker in the assessment of ovarian reserve. In this review, we provide a comprehensive summary of our current understanding of the biological role of inhibin, its relationship with activin, its signaling mechanisms, and its potential value as a diagnostic marker for reproductive function and pregnancy-associated conditions. |
